Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
FACT
MALARIA
Framework programme: 5
Project number:
ICA4-CT-2002-10046
EC contribution: € 1 163 698
Duration: 36 months
Type: RS
Starting date: 1 July 2002
Graphic element Development of Oral Fixed Dose Artesunate-Based Combinations for the Treatment of Uncomplicated Malaria

Summary:

This proposal aims at the fast-track pharmaceutical development and clinical validation of two artesunate-based fixed dose combinations for the treatment of malaria, including the preparation of relevant registration files. The goal is to make these new combination drugs available for use as quality, safe, viable, adapted and affordable drugs in the endemic countries. This project contributes a missing link in promoting antimalarial policy changes towards combination therapy, and the successful implementation thereof. It builds upon the expertise of R&D centres in the EU and different regions in the world, which are being mobilised in an international effort to improve dramatically the available malaria treatment tools.

Objectives:

Clinical trials and therapeutic experience have indicated that combinations of antimalarial drugs with different mechanisms of action, including artemisinin derivatives, improve therapy by preventing resistance. The success of the deployment of such drug combinations depends upon the availability of affordable fixed-dose combinations, adapted to the conditions of use. The proposal aims at promoting a therapeutic antimalarial policy change and the successful implementation thereof, by completing the development of quality, effective, safe, adapted and affordable fixed dose combinations of artesunate+mefloquine and artesunate+amodiaquine respectively. This will include preparing registration files and making the combination drug products available in the endemic countries by means of an international co-operation involving experts and institutes of the concerned countries.

Description:

The work will include six different types of activities:

1) Pre-clinical pharmaceutical development of the two fixed dose combination products (artesunate+mefloquine and artesunate+amodiaquine) for the generation of the Chemistry, Manufacturing and Control Sections (CMC) for the registration file and manufacturing of clinical batches. This will involve analytical and pharmaceutical sciences contributions.

2) Pre-clinical biological development and assessment, including a safety section (acute and adapted chronic administration) and a ‘mechanism of action’ contribution. This will require the development of adapted bioanalytical methods and conducting toxicokinetics studies in two animal species.

3) Clinical confirmation trials with the new formulations complementing existing data. This will also include an investigation of the bioavailability of the new combination.

4) Compilation of a registration documentation file, which can be submitted in the various malaria endemic countries.

5) Coordination of the work performed in different countries and regions.

6) Involvement in reviews and case studies with experts and authorities of the countries in which the new formulation will be developed and registered.

Milestones:

Year 1: Definition of the new formulations and scale-up of production. Pre-clinical safety and pharmacological data. Bioavailability of new formulations.

Year 2: Start of clinical studies. Identification of a manufacturing site.

Year 3: Clinical validation data. Stability analysis and reports. Registration of the new formulations.

Coordinator:

Jean-René Kiechel
Fondation Médecins sans Frontières
Access to Essential Medicines
75011 Paris
France
Tel: +33 1 64 92 20 65
Fax: +33 1 64 92 20 65
E-mail: jean-rene.kiechel@wanadoo.fr

Partners:

  1. Université Victor Segalen Bordeaux 2 - Cellule de Valorisation, FR-Bordeaux, France
  2. University of Oxford - Centre for Tropical Medicine, Nuffield, Department of Medicine, UK-Oxford, United Kingdom
  3. Universiti Sains Malaysia - Centre for Drug Research, Pulau Pinang, Malaysia
  4. Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  5. Instituto de Tecnologia Am Farmacos: Far-Manguinhos - Department of Pharmacotechnics / Far-Manguinhos: Fiocruz, Rio de Janeiro, Brazil
  6. World Health Organisation - UNDP/World Bank/ WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland
  7. Centre National de Recherche et de Formation sur le Paludisme – Cnre, Burkina Faso

 
 
top
Graphic element